8-K: BD Completes Biosciences & Diagnostic Solutions Spin-Off

Becton, Dickinson and Company announced the successful completion of the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation, receiving $4 billion in cash and distributing Waters common stock to shareholders.

Summary

• BD completed the spin-off of its Biosciences & Diagnostic Solutions business and combined it with Waters Corporation on February 9, 2026.
• BD shareholders received approximately 0.135 shares of Waters common stock for each BD common stock held as of February 5, 2026, plus cash for fractional shares.
• BD received $4 billion in cash from the transaction.
• BD shareholders now own 39.2% of the outstanding shares of the combined company (Waters Corporation) on a fully diluted basis.
• The transaction valued the spun-off business at $18.8 billion, based on Waters' closing price on February 6, 2026.
• BD plans to use $2 billion of the cash proceeds for an accelerated share repurchase program and the remaining $2 billion for debt repayment, both in the near term, subject to market conditions.
• Claire M. Fraser, Ph.D., resigned from BD's board and was appointed to Waters Corporation's board, reducing BD's board to twelve directors.
• Several definitive agreements were entered into: Tax Matters Agreement, Employee Matters Agreement, Intellectual Property Matters Agreement, and Transition Services Agreement.
• The Intellectual Property Matters Agreement includes a worldwide, fully paid, royalty-free, irrevocable, nonexclusive license between BD and Waters for their respective IP, and an exclusive license from BD to Waters for three patent families related to R&D-stage technology for biological fluid collection devices within the Biosciences and Diagnostics Solutions Business field.
• The Transition Services Agreement outlines services (HR, sales & marketing, finance, IT) BD will provide to SpinCo for a duration ranging from three months up to 24 months.
• An amendment to the Separation Agreement was made on February 9, 2026, to add definitions, modify the "Final SpinCo Cash" definition, amend Section 2.8(b) regarding intercompany agreements, add an office space in Germany to Schedule 1.7(a), and add Section 2.20 regarding shared real property costs (RMT Partner bears the first $1 million, then a 50/50 split for costs exceeding that).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive strategic move, successfully completing a major portfolio transformation and providing significant capital for shareholder returns and debt reduction, positioning BD for focused future growth.

Positives

• Successful completion of a major strategic transaction, marking the final milestone of the BD 2025 strategy.
• BD received a substantial $4 billion in cash proceeds.
• Planned use of proceeds includes $2 billion for share repurchases and $2 billion for debt repayment, expected to enhance shareholder value and improve financial health.
• The transaction positions BD as a "focused, pure-play MedTech company" aligned with its "Excellence Unleashed strategy."
• BD's portfolio has been deliberately shaped through divestitures and tuck-in acquisitions to strengthen its presence in attractive healthcare areas.
• The company expects to generate durable revenue, margin, and cash flow growth due to its global scale, leading market positions, and recurring consumables model.
• BD shareholders retain a significant stake (39.2%) in the combined Waters Corporation.

Risks

• Failure to realize the anticipated benefits of the transaction with Waters.
• Ability to execute the "Excellence Unleashed strategy."
• Uncertainties inherent in business and financial planning.
• Risks related to BD's business and prospects.
• Adverse developments in BD's markets.
• Adverse developments in the U.S. or global capital markets, credit markets, regulatory environment, or economies generally.
• Competitive developments.

Future Outlook

BD expects to use $2 billion of the cash distribution for share repurchases through an accelerated share repurchase program and the remaining $2 billion for debt repayments, both expected to be executed in the near term, subject to market conditions. The company is accelerating execution through its 'Excellence Unleashed strategy,' focusing on strengthening its commercial engine, leading with differentiated innovation, and delivering with exceptional quality and world-class operations. This strategy, combined with global scale, leading market positions, and a recurring consumables model, is expected to generate durable revenue, margin, and cash flow growth to drive shareholder value.

Management Comments

• "The successful combination of our Biosciences & Diagnostic Solutions business with Waters marks the final milestone of our BD 2025 strategy, positioning BD for its next chapter as a focused, pure-play MedTech company built for the next era of healthcare." Tom Polen, Chairman, CEO, and President of BD.
• "Over the last several years, we have deliberately shaped our portfolio — including divesting three substantial non-core assets and completing more than 20 strategic tuck-in acquisitions — to strengthen our presence in some of the most attractive areas in healthcare." Tom Polen.
• "As a result, BD is uniquely positioned to capitalize on the trends we’ve identified as shaping the future of healthcare: the rise of smarter connected devices and AI; the shift of care to more convenient settings; and rapid advances in technologies for chronic disease." Tom Polen.
• "Looking ahead, BD is accelerating execution through our Excellence Unleashed strategy — strengthening our commercial engine, leading with differentiated innovation, and delivering with exceptional quality and world-class operations." Tom Polen.
• "Combined with our global scale, leading positions in the majority of markets we serve, and highly recurring consumables model, we believe BD is well-positioned to generate durable revenue, margin, and cash flow growth to drive shareholder value." Tom Polen.
• "On behalf of the BD Board and management team, we thank Claire for her invaluable contributions to BD. Claire’s leadership and expertise in genomics, infectious diseases and molecular diagnostics have been instrumental in guiding our company through transformative periods and shaping the strategic direction of BD. She will provide significant expertise to Waters as part of their Board, and we wish her continued success." Tom Polen.

Industry Context

StockSavvy.ai notes that this divestiture aligns with a broader industry trend among diversified healthcare and life sciences companies to streamline portfolios and focus on core, high-growth segments. By spinning off its Biosciences & Diagnostic Solutions business, BD aims to become a more agile, pure-play MedTech company, potentially allowing for more targeted investment and innovation in its remaining segments. The focus on 'smarter connected devices and AI,' 'shift of care to more convenient settings,' and 'advances in technologies for chronic disease' reflects key strategic priorities across the MedTech sector, where companies are leveraging digital transformation and personalized medicine to drive future growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (BD): Received Waters common stock, cash for fractional shares, and benefit from planned share repurchases and debt reduction.
• Shareholders (Waters): BD shareholders now own 39.2% of Waters, potentially diversifying the shareholder base.
• Employees (SpinCo Group): Transferred to Waters Corporation, with provisions for comparable compensation and benefits, service credit, and assumption of certain liabilities by SpinCo/Waters.
• Employees (BD Group): Remain with BD, which is now a more focused MedTech company.
• Customers: The transaction aims to create more focused entities, potentially leading to better-served customers in both the MedTech and life sciences sectors.

Next Steps

• BD expects to use $2 billion for share repurchases through an accelerated share repurchase program in the near term, subject to market conditions.
• BD expects to use $2 billion for debt repayments in the near term, subject to market conditions.
• BD will accelerate execution through its "Excellence Unleashed strategy."
• The Company and RMT Partner will cooperate in good faith to separate shared facilities at certain real properties, with RMT Partner bearing the first $1 million in costs and then a 50/50 split for costs exceeding that.
• BD will provide certain transitional services (HR, sales & marketing, finance, IT) to SpinCo for a duration ranging from three months up to 24 months.

Key Dates

Recommendation

The successful completion of this strategic spin-off and combination is a significant positive for BD. The $4 billion cash infusion, earmarked for substantial share repurchases and debt reduction, directly enhances shareholder value and strengthens the company's balance sheet. The transformation into a focused, pure-play MedTech company, as outlined by the 'Excellence Unleashed strategy,' positions BD to capitalize on high-growth areas in healthcare, promising durable revenue and margin expansion. This strategic clarity and financial discipline make BD a compelling 'strong buy' for long-term investors.

Keywords

BD, Becton Dickinson, Waters Corporation, Spin-off, Divestiture, Merger, Biosciences, Diagnostic Solutions, MedTech, Healthcare, Share Repurchase, Debt Repayment, SEC Filing, 8-K, Corporate Strategy, Intellectual Property, Transition Services